PMI Presents to US FDA Advisory Committee; Important Milestone in the Scientific Review of IQOS
On January 24 and 25, experts from Philip Morris International Inc. (PMI) and Philip Morris USA Inc. presented to the Tobacco Products Scientific Advisory Committee (TPSAC) before the US Food and Drug Administration (FDA).
The meeting was part of the FDA’s review of PMI’s request to commercialize IQOS in the US as a “Modified Risk Tobacco Product”. U.S. law and policy recognize product innovation as important to the 40 million American men and women who smoke.
To advise the Agency on PMI’s applications, the Committee covered a wide range of scientific, technical, and consumer-communications topics. It raised questions and probed the likelihood and magnitude of potential benefits as well as how best to address possible unintended use.
Although the Committee did not agree with some of the specific language of proposed risk and harm consumer communications, it confirmed that the evidence supported the statement that switching completely to IQOS significantly reduces exposure to harmful chemicals.
“The Committee’s two-day discussion was a milestone event. We thank the Agency and the Committee for their interest in our scientific dossier and our determination to enable adults who smoke to have access to and information about better alternatives,” said André Calantzopoulos, PMI’s Chief Executive Officer, who added: “I am deeply grateful to my colleagues for their exceptional work on our application to the FDA and for the presentations last week. Our science and the commitment of our people give me confidence that we will realize our vision of a smoke-free future.”
We believe the Committee’s interactions with presenters and its discussion reflected respect for our scientific data and commitment to bring IQOS to the U.S. The Committee delved into such areas as inferences about long-term health outcomes, quantification and comparison of risk, the best way to formulate consumer information, and areas for post-market surveillance. At the end of the meeting, the Members of the Committee discussed and voted on particular questions on which the Agency requested the Committee’s views. TPSAC recommendations and votes are not binding on the FDA.
“As a next step, we look forward to working with the Agency to clarify outstanding points so as to best assist in their ongoing decision-making process, which inherently entails a certain degree of scientific uncertainty pre-market,” said Mr. Calantzopoulos, who concluded: “As the FDA routinely does with regard to the many products it regulates, I believe the Agency will ultimately address that uncertainty in the best interest of people who smoke.”
Since 2008, PMI has invested more than USD 3 billion in scientific research, product and commercial development, and production capacity related to IQOS and other smoke-free products. In 2017, over 70% of global R&D expenditure and over 30% of global commercial expenditure was allocated to smoke-free products, and we plan to invest more than USD 1.7 billion in facilities to manufacture them.
Nearly 4 million adult smokers have already switched to IQOS. Our ambition is that all those who would otherwise continue smoking abandon cigarettes and switch completely to scientifically substantiated smoke-free products as soon as possible. Regulatory policies and decisions can substantially accelerate the speed and magnitude of this historic change.
Note to the editor
The FDA is reviewing PMI’s MRTP applications pursuant to the provisions of a 2009 Statute that granted the Agency authority with respect to tobacco products. Under the Statute, the FDA’s decision takes account of scientific evidence as well as comments, data, and information submitted by interested persons.
As previously announced, in 2018 PMI will complete a 12-month exposure response study designed to measure clinical risk markers in adult smokers who switch to IQOS.
PMI has also submitted a Pre-Market Tobacco Application (PMTA) to the FDA which, if granted, will permit the commercialization of IQOS in the US without modified risk messages. This application was not before the Committee as it follows a separate regulatory pathway.
Under agreements with PMI, PM USA is licensed to sell IQOS in the U.S. should PMI receive a PMTA marketing order from the FDA.
Philip Morris International: Who We Are
We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products that are a much better choice than continuing to smoke cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirements. Our vision is that these products ultimately replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. For more information, see our PMI and PMIScience websites.
Philip Morris International media office
T: +41 (0)58 242 4500
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Corsair Infrastructure Partners Announces Transaction Involving DP World Australia23.1.2019 04:35 | Pressemelding
Corsair Infrastructure Partners (“CIP”), the global infrastructure investment business of Corsair Capital (“Corsair”), today announced that Gateway Infrastructure Investments (“Gateway”), an investment fund managed by CIP, as well as several other financial investors, have entered into agreements to sell their entire stakes in DP World Australia (Holding) Pty Ltd (“DPWA”) to DP World and new investment funds managed by CIP. The closing of the transaction is subject to regulatory approvals. As a result of this transaction, DP World, the original corporate parent of DPWA, will hold a majority stake in the company, alongside a substantial minority investment by CIP-managed funds. Hari R. Rajan, Managing Director of Corsair and Head of CIP, said, “We are pleased to have achieved the exit of Gateway’s investment in DPWA, while maintaining our strong relationship with DP World through our continued management of a large investment in the company. We believe this new shareholder structure wil
Yokogawa Joins Global 100 Most Sustainable Corporations in the World Index23.1.2019 04:00 | Pressemelding
Yokogawa Electric Corporation (TOKYO:6841) announces that it has been included in the 2019 Global 100 Most Sustainable Corporations in the World Index (Global 100). This is Yokogawa’s first time on the Global 100, one of the world's leading sustainability indices. Now in its 15th year, the 2019 Global 100 was disclosed in Davos on January 22nd by Corporate Knights, a Canadian media and research company focused on clean capitalism, to coincide with the World Economic Forum. To determine the 2019 ranking, Corporate Knights undertook a rigorous analysis of more than 7,500 companies with US$1B+ in revenues against global industry peers on a suite of up to 21 quantitative key performance indicators, weighted to reflect each industry’s impact profile. Yokogawa was ranked in the top 25% in both the clean revenues* and innovation capacity categories. In its core industrial automation and control business, Yokogawa works with customers in the energy, chemical, iron and steel, water, and other i
V-CAT to Begin a New Type of Crowdfunding, Using Digital Currency23.1.2019 00:00 | Pressemelding
V-CAT Vietnam will develop a new type of crowdfunding services that uses digital currency. A platform that uses the JC-coin digital currency will be built, and all data involved in transactions will be safely protected with leading-edge blockchain technology. Any user with JC-coins can exchange any physical or digital assets they might own on the platform for more JC-coins. This will provide the funding needed to develop revolutionary new products and services, together with users worldwide, and will enable new investments in all kinds of different businesses. V-CAT is proceeding with development of the MALLLESS platform in advance of an April 2019 launch of services. The goal is to host 10 million users worldwide by 2020. What makes MALLLESS unique is that businesses and individuals can take advantage of the point-transfer transaction model website and the proprietary wallet mechanism, both of which enable any selling of new or used goods, or of intangibles. There is also conversions
Prominent Trade Consulting Firm in South Korea Switches to Rimini Street Support for Its Oracle Database22.1.2019 23:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that EC21, a leading export marketing and trade consulting firm in Korea, has switched to Rimini Street support for its Oracle Database software. By switching to Rimini Street, EC21 is able to dramatically reduce the total cost of maintenance of its Oracle Database by approximately 75 percent, and improved productivity within its IT department as resources can be reallocated to more strategic projects across the organization. EC21 can also maintain its robust, stable database platform for a minimum of 15 years from the time the company moved to Rimini Street, avoiding any unnecessary upgrades just to retain full support from the vendor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005104/en/ Prominent Trade Consulting Fir
IFF to Release Fourth Quarter and Full Year 2018 Results February 1322.1.2019 21:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its fourth quarter and full year 2018 earnings results following the market close on Wednesday, February 13, 2019. The management team will host a live webcast on Thursday, February 14, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what i
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 201922.1.2019 21:05 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 3826138 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, February 6, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (int